Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oblimersen with Cisplatin and Fluorouracil in Advanced Esophageal and Gastric Cancer
NCT00064259Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2003
- Primary completion
- Feb 2010
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oblimersen in esophageal cancer, gastric cancer (GC) and gastroesophageal junction cancer, sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose (MTD) of Oblimersen in Combination With Cisplatin and 5-FU at 21 days. Started Jun 2003; status: terminated.
02
Drugs
oblimersen
03
Conditions
esophageal cancergastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT00064259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064259.